A randomized, open label, three way crossover relative bioavailability study in healthy adult male and female subjects to evaluate the bioavailability of GRC 4039 (1 mg and 5 mg) following single oral administration of a tablet formulation under fasting and fed conditions compared with that of a capsule in fasting condition.

Trial Profile

A randomized, open label, three way crossover relative bioavailability study in healthy adult male and female subjects to evaluate the bioavailability of GRC 4039 (1 mg and 5 mg) following single oral administration of a tablet formulation under fasting and fed conditions compared with that of a capsule in fasting condition.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Aug 2016

At a glance

  • Drugs Revamilast (Primary)
  • Indications Multiple sclerosis; Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Sponsors Glenmark Pharmaceuticals S.A.
  • Most Recent Events

    • 08 Feb 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top